RESUMO
BACKGROUND: Watch and wait (W&W) in complete clinical responders after neoadjuvant chemoradiotherapy has increasingly robust data supporting its oncological safety. Recently, studies have assessed the real-world costs of this strategy compared to surgical resection. Our aim was to compare our oncological safety and costs associated with operative and surveillance strategies to international literature. METHODS: Data were retrospectively collected and analysed via electronic health records from March 2014 to March 2021 in Christchurch, New Zealand. Two cohorts were created based on intention to treat. All hospital events were recorded and costed, as well as oncologic outcomes. Our primary endpoints were the cumulative cost of both strategies, 3-year survival rate, and disease-free survival. RESULTS: Forty-eight patients were identified who had rectal cancers resected (OT) with a yPT0N0 pathology, and 42 who were on the wait-and-watch (W&W) audit after having a clinical complete response. After exclusions, we identified 38 OT and 23 W&W patients; the W&W group were more co-morbid (P = 0.05), had worse functional status (P = 0.008), higher BMI (P = 0.34) and more favourable clinical tumour staging (P = 0.01). The operative treatment (OT) group (n = 38) had more acute admissions (34% versus 13% in W&W, P = 0.08, OR 0.29). There was a 35.7% (n = 8 of 23) local recurrence in W&W and none in the OT group (P ≤ 0.001), with successful salvage in the W&W with local recurrence in 71.5% (n = 5 of 7). Three-year distant metastasis-free rate was 97.3% in the OT group and 90.9% in W&W (p = 0.05). Overall survival was 100% (W&W) and 94.7% (OT); (P = 0.019). Care in the OT group cost more than W&W, accounting for local regrowth management; $NZ70,759.56 versus $NZ47,905.52 (P = 0.014). CONCLUSION: This study found better oncological outcomes in the OT group, whilst the W&W group had reduced morbidity and acute bed days. The cost of wait and watch was approximately two-thirds that of operative treatment, even accounting for salvage procedures for local regrowth.
Assuntos
Terapia Neoadjuvante , Neoplasias Retais , Conduta Expectante , Humanos , Neoplasias Retais/terapia , Neoplasias Retais/patologia , Neoplasias Retais/mortalidade , Masculino , Conduta Expectante/economia , Feminino , Estudos Retrospectivos , Pessoa de Meia-Idade , Idoso , Nova Zelândia/epidemiologia , Quimiorradioterapia/métodos , Quimiorradioterapia/economia , Resultado do Tratamento , Intervalo Livre de Doença , Taxa de Sobrevida , Estadiamento de Neoplasias , AdultoRESUMO
BACKGROUND: Acute diverticulitis (AD) is an increasingly common cause of acute hospital admissions. An understanding of its economic burden is necessary to plan resource allocation, and for targeting health research funding. The aim of this study is to obtain an accurate estimate of the cost of AD, accounting not only for the initial episode, but all related costs incurred during long-term follow-up. METHODS: The study captures a cohort of patients who had an initial admission for AD from 1 January 2012-31 December 2012, and their treatment over a 6-year period. Cases were identified from a prospectively maintained database, with AD confirmed by computed tomography scan. The primary outcome was total healthcare cost related to AD. RESULTS: The study included 170 patients. The total cost was NZD1 956 859 with a median cost per patient of NZD4814. A total of 57% of the cost was incurred for the initial inpatient admission, with the remaining 43% incurred through re-admission, follow-up appointments, investigations and management. Half of the total cost was incurred by 11.8% of the cohort. In multivariate analysis, high cost of care was significantly associated with complicated and recurrent disease, operative intervention and length of stay. CONCLUSION: This study provides an accurate estimate of the overall cost of AD and its sequelae. There are considerable long-term costs associated with the index episode and a large proportion of the expenditure is incurred by a small group that included those with complicated disease. These findings are important for healthcare resource allocation and for targeting health research funding.
Assuntos
Efeitos Psicossociais da Doença , Diverticulite , Diverticulite/epidemiologia , Diverticulite/terapia , Custos de Cuidados de Saúde , Hospitalização , Humanos , Estudos Longitudinais , Estudos RetrospectivosRESUMO
BACKGROUND: Colorectal cancer is a common and often fatal malignancy. Currently, the modifications that alter disease outcome include early symptom recognition, population screening as well as improved surgical and adjuvant treatments. Preventative strategies have been limited with little evidence that lifestyle changes significantly alter risk. There is however a growing awareness of a potential role for chemoprevention in some patient groups. This study aimed to review the literature associated with chemoprevention in colorectal cancer. METHODS: An electronic literature search of MEDLINE and Embase databases was performed on PubMed for studies detailing the use of chemoprevention agents in colon and rectal cancer. The search was limited to clinical trials on adult humans (>16 years of age) published in English since 1990. RESULTS: The strongest evidence is for non-steroidal anti-inflammatory drugs slowing polyp progression, notably Sulindac and aspirin in patients with familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, respectively. There is also increasing evidence that continuing use of low-dose aspirin reduces long-term incidence of colorectal cancers. Cyclooxygenase 2 inhibitors also have a potential role but cardiac toxicity currently limits their use. Folic acid, statins, antioxidants, calcium and 5-aminosalicylic acid lack evidence to support their use at present. CONCLUSIONS: Currently, there is not enough evidence to support the implementation of a chemopreventative agent for general use. However, there appears to be a role for aspirin in selected subgroups.
Assuntos
Polipose Adenomatosa do Colo/prevenção & controle , Quimioprevenção/efeitos adversos , Quimioprevenção/métodos , Neoplasias Colorretais Hereditárias sem Polipose/prevenção & controle , Neoplasias Colorretais/prevenção & controle , Polipose Adenomatosa do Colo/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Inflamatórios não Esteroides/uso terapêutico , Aspirina/uso terapêutico , Cardiotoxicidade/complicações , Quimioprevenção/economia , Ensaios Clínicos como Assunto , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/epidemiologia , Neoplasias Colorretais Hereditárias sem Polipose/tratamento farmacológico , Inibidores de Ciclo-Oxigenase 2/efeitos adversos , Inibidores de Ciclo-Oxigenase 2/uso terapêutico , Progressão da Doença , Humanos , Incidência , Metanálise como Assunto , Pessoa de Meia-Idade , Sulindaco/uso terapêutico , Adulto JovemAssuntos
Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/terapia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Prevenção Primária/organização & administração , Melhoria de Qualidade/organização & administração , Neoplasias Colorretais/economia , Neoplasias Colorretais/epidemiologia , Gerenciamento Clínico , Diagnóstico Precoce , Humanos , Nova Zelândia/epidemiologia , Avaliação de Processos e Resultados em Cuidados de SaúdeRESUMO
New Zealand has one of the highest incidences of rectal cancer in the world, and its optimal management requires a multidisciplinary approach. A National Rectal Cancer Summit was convened in August 2013 to discuss management of rectal cancer in the New Zealand context, to highlight controversies and discuss domestic priorities for the future. This paper summarises the priorities for treatment, research and policy for rectal cancer services in New Zealand identified as part of the Summit in August. The following priorities were identified: - Access to high-quality information for service planning, review of outcomes, identification of inequities and gaps in provision, and quality improvement; - Engagement with the entire sector, including private providers; - Focus on equity; - Emerging technologies; - Harmonisation of best practice; - Importance of multidisciplinary team meetings. In conclusion, improvements in outcomes for patients with rectal cancer in New Zealand will require significant engagement between policy makers, providers, researchers, and patients in order to ensure equitable access to high quality treatment, and strategic incorporation of emerging technologies into clinical practice. A robust clinical information framework is required in order to facilitate monitoring of quality improvements and to ensure that equitable care is delivered.
Assuntos
Efeitos Psicossociais da Doença , Gerenciamento Clínico , Equipe de Assistência ao Paciente/organização & administração , Neoplasias Retais , Gestão da Qualidade Total/métodos , Adulto , Congressos como Assunto , Etnicidade , Feminino , Política de Saúde , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Avaliação das Necessidades , Nova Zelândia/epidemiologia , Neoplasias Retais/diagnóstico , Neoplasias Retais/economia , Neoplasias Retais/epidemiologia , Neoplasias Retais/terapia , Pesquisa , Fatores de Risco , Fatores SocioeconômicosRESUMO
Introducing a new disclosure form for member journals of the International Committee of Medical Journal Editors.